CRDL 株価分析 — Cardiol Therapeutics Inc Class A (Healthcare >> Drug Manufacturers - Specialty & Generic)
CRDL に関するよくある質問
CRDLのROE(自己資本利益率)は?
Cardiol Therapeutics Inc Class AのROEは-149.91%です。
CRDLの配当利回りは?
Cardiol Therapeutics Inc Class Aの配当利回りは0.00%です。
CRDLの品質スコア(Quality Score)は?
当社のAIはCRDLの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
CRDLは今が買い時ですか?
当社AIのタイミングスコアは100点中91点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
CRDLはどのセクターに属しますか?
Cardiol Therapeutics Inc Class AはHealthcare >> Drug Manufacturers - Specialty & Genericセクターに分類されます(NASDAQ市場)
CRDL AI Analysis Summary
Our AI summary for CRDL: Cardiol Therapeutics Inc Class A (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 0.00, ROE of -149.91%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1.34
Price
-0.02
(-1.47%)
Day Change
|
|
|---|
CRDL, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) but テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.34 |
| PBV / Sector |
6.46 / 10.19
|
| Earning Per Share | -0.31 |
| PE / Sector |
N/A / 31.74
|
| PEG or PE/Growth / Sector |
N/A / -0.02
|
| Average 1M Daily Value |
1.28 M
GREAT
|
| Average 1W Daily Value |
1.41 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-06 07:59:49 |
| Symbol | CRDL |
| Name | CARDIOL THERAPEUTICS INC CLASS A |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 115.27 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 156.77 / 10,556.24 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2265 Upper Middle Road East, Oakville, ON, Canada, L6H 0G5
Phone: 289 910 0850
Website: https://www.cardiolrx.com
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Google